Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Combined speech pathology and amitriptyline treatment for vocal cord dysfunction.
Scientific title
Comparison of combined speech pathology and amitriptyline versus speech pathology alone in the treatment of vocal cord dysfunction: a randomised double-blind placebo controlled trial.
Secondary ID [1] 297230 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Vocal Cord Dysfunction 311318 0
Condition category
Condition code
Respiratory 309955 309955 0 0
Other respiratory disorders / diseases

Study type
Description of intervention(s) / exposure
Arm 1 - Amitriptyline 25mg per day for one week, then increased to 50mg per day for one week then increased to maximal dose of 75mg per day for 8 weeks, oral route - oral capsules, combined with speech pathology behavioural intervention. Speech pathology intervention includes education on vocal cord dysfunction and related conditions such as chronic refractory cough, provision of lifestyle strategies, vocal hygiene and behavioural breathing and voice exercises, provided on an individual basis for 5 sessions over 10 weeks, provided by an experienced speech pathologist.
Arm 2 - Placebo medication and identical speech pathology behavioural intervention.
Adherence to medication and speech pathology intervention will be monitored by unused product return (medication) and participant diary and participant explanation and modelling of exercises (speech pathology intervention).
Intervention code [1] 313500 0
Treatment: Drugs
Intervention code [2] 313501 0
Treatment: Other
Comparator / control treatment
Prosolv cellulose placebo , oral route in combination with speech pathology intervention
Control group

Primary outcome [1] 318869 0
vocal cord dysfunction symptoms as assessed by - Vocal Cord Dysfunction Questionnaire (VCDQ)
Timepoint [1] 318869 0
Baseline and post treatment - week 11
Secondary outcome [1] 366289 0
throat hypersensitivity symptoms including irritation, pain and obstruction as assessed by an overall composite score on the Laryngeal Hypersensitivity Questionnaire (LHQ)
Timepoint [1] 366289 0
baseline and post treatment - week 11
Secondary outcome [2] 366290 0
auditory - perceptual voice measure using the Consensus Auditory Perceptual Evaluation of Voice (CAPE-V)
Timepoint [2] 366290 0
baseline and post treatment - week 11
Secondary outcome [3] 366291 0
voice quality of life measure using the Voice Handicap Index (VHI)
Timepoint [3] 366291 0
baseline and post treatment - week 11
Secondary outcome [4] 366292 0
anxiety and depression measure using the Hospital Anxiety and Depression Scale (HADS)
Timepoint [4] 366292 0
baseline and post treatment - week 11

Key inclusion criteria
Adults with vocal cord dysfunction diagnosed using laryngoscopy. Diagnosis defined as abnormal adduction of the vocal folds during inspiration or > 50% adduction during expiration.
Minimum age
18 Years
Maximum age
85 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
previous speech pathology treatment for vocal cord dysfunction
contraindications for the use of amitriptyline including pregnancy and breast feeding
Lung pathology excluding asthma
progressive neurological condition
structural vocal fold pathology
inability to attend study visits

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
allocation concealment - central randomisation within the Pharmacy Clinical Trials Unit for active or placebo allocation. Participants and study investigators blinded to allocation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Stratified block randomisation. Stratified for age and referral source - ENT or Respiratory Physician
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 13011 0
The Alfred - Prahran
Recruitment postcode(s) [1] 25496 0
3004 - Prahran

Funding & Sponsors
Funding source category [1] 301780 0
Name [1] 301780 0
The Alfred
Address [1] 301780 0
Commercial Rd Prahran
Victoria 3004
Country [1] 301780 0
Primary sponsor type
LaTrobe University
Bundoora, Victoria 3083
Secondary sponsor category [1] 301522 0
Name [1] 301522 0
Alfred Health
Address [1] 301522 0
The Alfred, Commercial Rd Prahran
Victoria 3004
Country [1] 301522 0

Ethics approval
Ethics application status
Ethics committee name [1] 302496 0
Alfred Health HREC
Ethics committee address [1] 302496 0
Office of Research and Ethics
Alfred Health
Level 5/553 St Kilda Rd
Victoria 3004
Ethics committee country [1] 302496 0
Date submitted for ethics approval [1] 302496 0
Approval date [1] 302496 0
Ethics approval number [1] 302496 0
Ethics committee name [2] 302516 0
LaTrobe University HREC
Ethics committee address [2] 302516 0
LaTrobe University, Bundoora
Victoria 3083
Ethics committee country [2] 302516 0
Date submitted for ethics approval [2] 302516 0
Approval date [2] 302516 0
Ethics approval number [2] 302516 0

Brief summary
The purpose of this study is to trial a combination treatment of speech pathology and amitriptyline for vocal cord dysfunction and compare this to speech pathology alone. The aim is to reduce the symptoms of vocal cord dysfunction.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 90418 0
Mrs Janine Mahoney
Address 90418 0
Speech Pathology Dept
The Alfred
Commercial Rd
Victoria 3004
Country 90418 0
Phone 90418 0
+61 390763341
Fax 90418 0
Email 90418 0
Contact person for public queries
Name 90419 0
Mrs Janine Mahoney
Address 90419 0
Speech Pathology Dept
The Alfred
Commercial Rd
Victoria 3004
Country 90419 0
Phone 90419 0
+61 390763341
Fax 90419 0
Email 90419 0
Contact person for scientific queries
Name 90420 0
Mrs Janine Mahoney
Address 90420 0
Speech Pathology Dept
The Alfred
Commercial Rd
Victoria 3004
Country 90420 0
Phone 90420 0
+61 390763341
Fax 90420 0
Email 90420 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
group data will be available through publication
What supporting documents are/will be available?
No other documents available
Summary results
No Results